#39 – Part One: Has Atai Life Sciences Taken the Psychedelic Throne From MAPS?
Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences’ recent IPO on Nasdaq. They also discuss and provide updates on Russell’s previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits.
Co-hosts: Brian Normand, David Nickles, Russell Hausfeld, Sarvesh Ramprakash. Editor: Matt Payne
Plus Three goes deep into the world of drugs, from local decriminalization and emerging psychedelic corporations, to leftist politics and mass incarceration. Each week we attempt to make sense of the complex connections between drugs, science, capitalism, policy, and culture.
Psymposia is a 501(c)(3) non-profit media organization. We depend on contributions from our readers and listeners, never ads. If you like the show please donate or support us on Patreon. Patreon supporters get bonus videos and more.
The post #39 – Part One: Has Atai Life Sciences Taken the Psychedelic Throne From MAPS? appeared first on Psymposia.psychedelic ipo nasdaq atai life sciences atai decriminalization